Zektayos - Hepjuvo (obeticholic acid)
- Region
- 🇪🇺 EU
- Active substance
- obeticholic acid
- Company
- Advanz Pharma Limited
- Status
- Application withdrawn
- Therapeutic area
- Fatty Liver
- Application
- EMEA/H/C/005249
- ATC
- A05AA04
- Official record
- www.ema.europa.eu
Indication
Improvement of liver fibrosis and resolution of steatohepatitis in adult patients with significant liver fibrosis due to nonalcoholic steatohepatitis (NASH)
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Ocaliva Revoked · Advanz Pharma Limited
Follow Zektayos - Hepjuvo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.